Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza vaccine (split virion, inactivated, quadrivalent)
- Development stage
- Approved
- Lead developer
- Instituto Butantan
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Butantan Foundation's quadrivalent influenza vaccine is an inactivated, fragmented (split-virion) vaccine developed for the prevention of seasonal influenza. Produced using traditional egg-based technology, the vaccine incorporates antigens from four distinct influenza virus strains: two Influenza A subtypes (typically A/H1N1 and A/H3N2) and two Influenza B lineages (B/Victoria and B/Yamagata). The vaccine works by inducing the host's immune system to produce neutralizing antibodies against the viral hemagglutinin (HA) and neuraminidase (NA) surface proteins, which are essential for viral attachment and release. This quadrivalent formulation provides broader protection compared to trivalent vaccines by covering both circulating B-strain lineages. It is a cornerstone of the Brazilian National Immunization Program (PNI) and is manufactured locally by the Butantan Foundation.
- Brand names
- Vacina Influenza tetravalente (fragmentada e inativada)
- Other names
- Butantan quadrivalent influenza vaccineButantan tetravalent influenza vaccineVacina Influenza tetravalente
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on influenza vaccine (split virion, inactivated, quadrivalent).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza vaccine (split virion, inactivated, quadrivalent).